BioVersys

arcoris bio provides spatial multiomics solutions focused on transforming biomedical research and diagnostics.

HemostOD manufactures platelets on-demand from engineered stem cells.

DropGen focuses on cutting-edge lab technology that enables the precise control of very small droplets within patterned microarrays.

Pharvaris is a clinical-stage company working on bringing a new oral bradykinin B2 receptor antagonist to patients as an alternative to injected therapies for hereditary angioedema and other related conditions. Their lead drug candidate, PHA121, is a potent small-molecule bradykinin B2 receptor antagonist currently in Phase 1 clinical study. The co-founders of Pharvaris include the inventor of icatibant and key leaders from Jerini AG, who developed icatibant for HAE treatment, now marketed as Firazyr® by Takeda.

Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance within the body. This system is designed to move excess fluid to the bladder, where it is passed naturally from the body through normal urination. Sequana Medical’s first product, the Alfapump System, is an innovative solution for the management of ascites. Ascites is a fluid that collects in the abdominal cavity in people with advanced liver disease, certain cancers, or congestive heart failure. Alfapump System was the first and only system for the automatic and continual removal of ascites. Sequana Medical was founded in 2006 and is based in Zurich, Switzerland.

A Swiss medical technology business called Medyria develops systems for endovascular catheter navigation and sensing. The goal of Medyria is to speed up, secure, and improve catheter-based treatments. In Technopark in Winterthur, Switzerland, Medyria is headquartered.

SEITO Biologics is a new biotechnology startup in the preclinical stage, focused on developing creative immunotherapies for autoimmune and chronic inflammatory conditions.

ReproNovo is changing the landscape of reproductive medicine and women's health by pushing boundaries and introducing cutting-edge treatments for infertility and uterine conditions such as adenomyosis. Our experienced international team is well-versed in reproductive medicine, drug development, regulatory strategy, and business development, with a successful history of bringing new therapies to the market. Backed by top investors, including Jeito Capital and M Ventures, our headquarters are in Lausanne, Switzerland, with development teams in Copenhagen, Denmark and Barcelona, Spain. Contact us at info@repronovo.com for more information. Meet our leadership team: CEO & Co-Founder Jean Duvall, Chief Scientific & Medical Officer & Co-Founder Joan-Carles Arce, and Chief Financial Officer & Co-Founder BingMei Hao.

HAYA Therapeutics is a company that develops RNA-based treatments for heart failure. Their therapies target a specific regulator of fibrosis in the heart, known as long noncoding RNA, in order to block myocardial fibrosis and effectively treat heart failure.

Granite Bio is a biotechnology company working on creating new antibodies for the treatment of inflammatory, autoimmune, and fibrotic diseases.

MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new therapies and harnessing the potential of Sonelokimab, a novel investigational Nanobody®, to transform results for patients experiencing inflammation.

SamanTree Medical is a pioneering medical device company from Switzerland that offers an innovative imaging solution that has the potential to enhance patient care and improve the results of cancer surgery. Their solution, which is based on confocal microscopy, allows surgeons to have precise and comprehensive control over margins during surgery.